NovoCure的Optune Lua®在日本获得监管批准，用于治疗不可切除的晚期/复发性非小细胞肺癌。
这一批准标志着该创新治疗设备在日本市场的重要进展，为当地非小细胞肺癌患者提供了新的治疗选择。Optune Lua®是专门针对不可切除的晚期或复发性非小细胞肺癌患者设计的治疗方案。
此次在日本获得批准，进一步扩大了NovoCure在亚洲市场的治疗覆盖范围，为更多肺癌患者带来希望。
NovoCure的Optune Lua®在日本获得监管批准，用于治疗不可切除的晚期/复发性非小细胞肺癌。
这一批准标志着该创新治疗设备在日本市场的重要进展，为当地非小细胞肺癌患者提供了新的治疗选择。Optune Lua®是专门针对不可切除的晚期或复发性非小细胞肺癌患者设计的治疗方案。
此次在日本获得批准，进一步扩大了NovoCure在亚洲市场的治疗覆盖范围，为更多肺癌患者带来希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.